The findings from in vitro experiments demonstrated that the inhibition of PATZ1 in thyroid cancer cells resulted in a decrease in the biological activity of p53, hence promoting both epithelial-mesenchymal transition (EMT) and cellular migration. Here, TP53 is linked to thyroid gland carcinoma.